Mark Purcell

Johnson & Johnson's (NYSE: JNJ) new hepatitis C drug Olysio helped it beat third quarter Street views, but an analyst cautioned the product may have hit a high water mark. Gilead Sciences, Inc. (NASDAQ: GILD) obtained approval this week for its competing Harvoni drug that Barclays'...

In a report released Wednesday, Barclays analyst Mark Purcell increases his price target for Pfizer (NYSE: PFE) from $32 to $34 per share, maintaining an Equal-Weight rating. Analyst at Barclays are more bullish on the pharmaceutical sector, favoring Pfizer's potential for organic growth....

Shares of Bristol-Myers Squibb (NYSE: BMY) are trading lower after Barclays cut the company from Overweight to Equal-weight and reduced the price target from $65 to $46. Barclays is not a huge fan of the pharmaceutical industry as a whole right now, citing modest growth and pipelines that...

In a report published Tuesday, Barclays analyst Mark Purcell downgraded the sector view for U.S. Pharma majors from Positive to Neutral. Despite concern over the "increasingly crowded commercial environment," the analyst sees a 22 percent upside for AbbVie (NYSE: ABBV). ...

In a note released Wednesday morning, Barclays analyst Mark Purcell upgraded shares of Eli Lilly (NYSE: LLY) from Underweight to Equal-weight and raised the price target from $51 to $63, despite downgrading his U.S. Pharma sector view from Positive to Neutral. Purcell wrote, "The sector...